PlainPharmaWatch

CMS Open Payments · Tool

Optinose US, Inc. vs Djo, LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Djo, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 830, versus 196 for the other company. Its single largest recorded recipient represents 0.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Optinose US, Inc.
HHI 196 · top recipient 0.1%
Ranked #1,564 of 1,838 companies by HHI
Djo, LLC
HHI 830 · top recipient 0.2%
Ranked #1,104 of 1,838 companies by HHI

Payment Overview

Company A

Optinose US, Inc.

Total Payments
$1.4M
% of Industry
0.0%
Transactions
14,061
Avg per Transaction
$98.42
Recipients
14,036
Avg per Recipient
$98.59
Payment Types
6
Top Payment Type
Compensation for Services Other Than Consulting
Company B

Djo, LLC

Total Payments
$1.4M
% of Industry
0.0%
Transactions
3,532
Avg per Transaction
$391.64
Recipients
3,527
Avg per Recipient
$392.20
Payment Types
9
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Optinose US, Inc. vs Djo, LLC - total reported payments in CMS Open Payments PY2024

Optinose US, Inc.$1.4MDjo, LLC$1.4M

Payment Types Breakdown

Optinose US, Inc.

Compensation for Services Other Than Consulting $790.3K

57.1%

Food and Beverage $346.8K

25.1%

Travel and Lodging $85.9K

6.2%

Consulting Fee $52.3K

3.8%

Space Rental or Facility Fees $12.8K

0.9%

Education $6.0K

0.4%

Djo, LLC

Royalty or License $761.8K

55.1%

Grant $256.2K

18.5%

Consulting Fee $109.4K

7.9%

Food and Beverage $98.3K

7.1%

Compensation for Services Other Than Consulting $58.9K

4.3%

Debt Forgiveness $44.0K

3.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Optinose US, Inc.

  1. 1

    NAVEEN BHANDARKAR

    $100,242.61 · 79 txns

  2. 2

    JEFFREY BEDROSIAN

    $90,728.47 · 80 txns

  3. 3

    MARK MEHLE

    $45,365.24 · 38 txns

  4. 4

    SUBINOY DAS

    $41,986.15 · 41 txns

  5. 5

    KEVIN MCLAUGHLIN

    $38,128.62 · 34 txns

Djo, LLC

  1. 1

    WILLIAM NORDT

    $304,249.19 · 4 txns

  2. 2

    BENJAMIN DOMB

    $196,098.35 · 4 txns

  3. 3

    THOMAS EDWARDS

    $72,739.22 · 4 txns

  4. 4

    SUMANT KRISHNAN

    $72,739.22 · 4 txns

  5. 5

    BRIAN COLE

    $35,262.34 · 8 txns

Summary Comparison

Metric Optinose US, Inc. Djo, LLC
Total Payments $1.4M $1.4M
% of Industry Total 0.0% 0.0%
Transaction Count 14,061 3,532
Avg per Transaction $98.42 $391.64
Recipient Count 14,036 3,527
Avg per Recipient $98.59 $392.20
Payment Type Count 6 9
Top Payment Type Compensation for Services Other Than Consulting Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.